Skip to content

Microdosing research published in 2022

Page 2 of 2: studies 21 to 27 of 27, newest first. Back to the microdosing overview

Studies

Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple’s therapy: a qualitative insight

Sexual & Relationship Therapy February 28, 2022 Lucy Jacobs, S. Banbury, J. Lusher

Abstract Background: Research has predominated among the therapeutic application of psychedelics for varied psychopathologies and yet remains limited when supporting sexual behaviour intimacy among couples; particularly those who micro-dose. Method: Using semi-structured interviews, this qualitative study explored the micro-dosing sexual experiences of four partnered men and women aged 20–35...

Microdosing as a Response to the Meaning Crisis: A Qualitative Analysis

Journal of Humanistic Psychology February 14, 2022 Rotem Petranker, Juensung J. Kim, Thomas Anderson

The use of psychedelic substances in both humanistic and mainstream clinical research has been increasing in the last decade. In particular, the practice of microdosing—ingesting sub-hallucinogenic doses of psychedelics—has been increasing in popularity, but large-scale qualitative analyses are still uncommon. This study attempted to recognize emergent themes in qualitative reports regarding...

A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold‐labeled venetoclax, from chemistry to the clinic

Clinical and Translational Science January 8, 2022 Amr Alaarg, Rajeev S Menon, David Rizzo et al.

Abstract This work presents an end‐to‐end approach for assessing the absolute bioavailability of highly hydrophobic, poorly water‐soluble compounds that exhibit high nonspecific binding using venetoclax as a model drug. The approach utilizes a stable labeled i.v. microdose and requires fewer resources compared with traditional approaches that use radioactive 14C‐labeled compounds. The stable...

Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin

Clinical Pharmacokinetics January 7, 2022 Z. Oesterreicher, Sabine Eberl, B. Wulkersdorfer et al.

Background and Objective In microdose studies, drug pharmacokinetics is measured in humans after administration of subtherapeutic doses. While previous microdose studies focused primarily on plasma pharmacokinetics, we set out to evaluate the feasibility of microdosing for a pharmacokinetic assessment in subcutaneous tissue and epithelial lining fluid. Methods Healthy subjects received a single...

Microdosing: Knowledge Distillation for GAN based Compression

arXiv Preprint Archive January 7, 2022 Leonhard Helminger, Roberto Azevedo, Abdelaziz Djelouah et al. preprint

Recently, significant progress has been made in learned image and video compression. In particular the usage of Generative Adversarial Networks has lead to impressive results in the low bit rate regime. However, the model size remains an important issue in current state-of-the-art proposals and existing solutions require significant computation effort on the decoding side. This limits their...

"O USO TERAPÊUTICO INDEPENDENTE DE MICRODOSAGEM DE PSILOCIBINA SOB PROTOCOLO FADIMAN : UM DIÁRIO DO AUTO-CONHECIMENTO"

Anais do 14º Congresso Brasileiro de Naturologia: Paradigmas contemporâneos da saúde mental e as novas perspectivas da medicina botânica 2022 Priscila Franco Saraiva Monteiro

A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero Psilocybe, como P. azurescens, P. semilanceata e P. c

DOI: 10.29327/1147850.14-1 (opens in new tab) Sub-perceptual dosing Psilocybin microdosing Low-dose psilocybin Psychedelic microdosing +14

Dosing Psychedelics and MDMA.

Current Topics in Behavioral Neurosciences 2022 Matthias E. Liechti, Friederike Holze 35 citations

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others....

DOI: 10.1007/7854_2021_270 (opens in new tab) Full text (opens in new tab) Microdosing Ego-dissolution dose Good effect dose Personalized medicine +1